EUVIMEDEUVIMED entdecken
Open Access · CC0

Web-based survey investigating cardiovascular complications in hypermobile Ehlers-Danlos syndrome after COVID-19 infection and vaccination

Anthony L Guerrerio iD, Allyson Mateja, Gretchen MacCarrick, Jonathan Fintzi, Erica Brittain, Pamela A Frischmeyer-Guerrerio, Harry C Dietz

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0298272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Anthony L Guerrerio und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, U…. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Ehlers-Danlos Syndrome, Heart Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NCI NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hypermobile Ehlers-Danlos syndrome is a heritable connective tissue disorder associated with generalized joint hypermobility but also other multisystem comorbidities, many of which may be exacerbated during a viral illness or after a vaccination. We sought to determine whether individuals with hypermobile Ehlers Danlos syndrome report an increase in adverse events, including cardiovascular events, after COVID-19 illness or vaccination.

Methods

A cross-sectional web-based survey was made available from November 22, 2021, through March 15, 2022. 368 respondents primarily from the United States self-reported data including diagnosis. We used a Cox proportional hazards model with time varying indicators for COVID-19 illness or vaccination in the previous 30 days.

Results

We found a significantly increased rate of new abnormal heart rhythms reported in the 30 days following COVID-19 illness. No additional cardiovascular events were reported after COVID-19 illness. 2.5% of respondents with COVID-19 illness were hospitalized. We did not find a statistically significant increased rate of cardiovascular events in the 30 days following any COVID-19 vaccination dose. Post COVID-19 vaccination, 87.2% of hypermobile Ehlers-Danlos syndrome respondents endorsed an expected adverse event (EAE), and 3.1% reported an emergency department visit/hospitalization, of those who received at least one vaccine dose. Events possibly reflecting exacerbation of orthostasis/dysautonomia were common.

Conclusion

Respondents did not report an increased rate of any cardiovascular events in the 30 days following COVID-19 vaccination; however, those with hypermobile Ehlers-Danlos syndrome experienced a high rate of expected adverse events after vaccination consistent with a high baseline prevalence of similar symptoms. No cardiovascular events other than new abnormal heart rhythms were reported at any point after a COVID-19 illness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesEhlers-Danlos SyndromeHeart DiseasesJoint InstabilityHumansCross-Sectional StudiesInternetSurveys and QuestionnairesVaccination

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
  • Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
  • McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
  • Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • The Laboratory of Allergic Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America.

ORCID-Profile: Anthony L Guerrerio

Förderung

  • NCI NIH HHS
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  • National Cancer Institute
  • Howard Hughes Medical Institute

Zitieren

APA

Guerrerio, A. L., Mateja, A., MacCarrick, G., Fintzi, J., Brittain, E., Frischmeyer-Guerrerio, P. A., & Dietz, H. C. (2024). Web-based survey investigating cardiovascular complications in hypermobile Ehlers-Danlos syndrome after COVID-19 infection and vaccination. PLOS ONE. https://doi.org/10.1371/journal.pone.0298272

Vancouver

Guerrerio AL, Mateja A, MacCarrick G, Fintzi J, Brittain E, Frischmeyer-Guerrerio PA, et al. Web-based survey investigating cardiovascular complications in hypermobile Ehlers-Danlos syndrome after COVID-19 infection and vaccination. PLOS ONE. 2024. doi:10.1371/journal.pone.0298272

BibTeX
@article{Guerrerio2024,
  author = {Guerrerio, Anthony L and Mateja, Allyson and MacCarrick, Gretchen and Fintzi, Jonathan and Brittain, Erica and Frischmeyer-Guerrerio, Pamela A and Dietz, Harry C},
  title = {Web-based survey investigating cardiovascular complications in hypermobile Ehlers-Danlos syndrome after COVID-19 infection and vaccination},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0298272}
}
Kostenlos starten →